COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Insole on Morton's Neuroma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03511677
Recruitment Status : Completed
First Posted : April 30, 2018
Last Update Posted : April 30, 2018
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Information provided by (Responsible Party):
Hilda Alcantara Veiga de Oliveira, Federal University of São Paulo

Brief Summary:

Objective: The aim of the present study was to assess the effectiveness of insole with metatarsal support on pain in patients with Morton's neuroma and the impact of this insole on function, load distribution in the plantar region, gait variables, quality of life and satisfaction with insole use.

Methods: A randomized, controlled, double-blind, clinical trial with intent-to-treat analysis. Seventy-two patients with Morton's neuroma were randomly allocated into a study group and control group. One week following the baseline evaluation, the study group received insole with metatarsal support made of ethyl vinyl acetate and the control group received a flat insole of the same material, color and density. The groups were evaluated after 6, 12 and 24 weeks of insole use. The following assessment parameters employed: pain when walking and at rest (END); quality of life (SF-36); foot function (FFI and FHSQ); six-minute walk test (6MWT) and foot pressure analysis using the AM Cube FootWalk Pro program.

Condition or disease Intervention/treatment Phase
Morton Neuroma Device: Insole Device: Placebo Insole Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Placebo insole
Primary Purpose: Treatment
Official Title: Effectiveness of Insole on Morton's Neuroma
Actual Study Start Date : June 1, 2015
Actual Primary Completion Date : March 31, 2018
Actual Study Completion Date : March 31, 2018

Arm Intervention/treatment
Experimental: Intervention Group
Customized insole with metatarsal support
Device: Insole
Customized insole

Placebo Comparator: Control Group
Placebo flat insole
Device: Placebo Insole
Placebo flat insole

Primary Outcome Measures :
  1. Change in pain [ Time Frame: Baseline, after 6, 12 and 24 weeks ]
    Measured by visual analogue scale from 0 cm to 10 cm

Secondary Outcome Measures :
  1. Change in function and foot health [ Time Frame: Baseline, after 6, 12 and 24 weeks ]
    Measured by Foot function index questionnaire

  2. Change in function, foot healt and quality of life [ Time Frame: Baseline, after 6, 12 and 24 weeks ]
    Measured by Foot Health Status questionnaire

  3. Change in function [ Time Frame: Baseline, after 6, 12 and 24 weeks ]
    Measured by the distance in the six minute walking test

  4. Quality of life [ Time Frame: Baseline, after 6, 12 and 24 weeks ]
    Measured by the Short Form -36 questionnaire

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with clinical and radiological diagnosis (magnetic resonance or ultrasound) of Morton's neuroma.
  • Pain in the foot with VAS between 3-8 cm to walk.
  • Over 18 years.
  • No distinction of sex
  • Agree to participate of the study and sign the informed consent form.

Exclusion Criteria:

  • Other symptomatic musculoskeletal diseases in MMII.
  • Symptomatic diseases of the central and peripheral nervous system.
  • Diabetes Mellitus.
  • Rigid deformities on foot.
  • Use of insoles in the last three months.
  • Physiotherapy in the last three months.
  • Infiltrations on foot and ankles in the last three months.
  • Previous or expected surgery in the next twelve months.
  • Allergy to the material of the insole.
  • Mental deficiency.
  • Geographic inaccessibility .- Use of corticosteroids or NSAIDs in the last month
Layout table for additonal information
Responsible Party: Hilda Alcantara Veiga de Oliveira, PT, MsC, Federal University of São Paulo Identifier: NCT03511677    
Other Study ID Numbers: 20634013.9.0000.5505.
First Posted: April 30, 2018    Key Record Dates
Last Update Posted: April 30, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hilda Alcantara Veiga de Oliveira, Federal University of São Paulo:
Morton Neuroma
Additional relevant MeSH terms:
Layout table for MeSH terms
Morton Neuroma
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Foot Diseases
Musculoskeletal Diseases
Joint Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations